Caxton Associates (New York)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $454K | Buy |
637
+49
| +8% | +$34.9K | 0.01% | 348 |
|
|
2024
Q3 | $618K | Sell |
588
-562
| -49% | -$591K | 0.02% | 327 |
|
|
2024
Q2 | $1.21M | Buy |
+1,150
| New | +$1.21M | 0.04% | 219 |
|
|
2024
Q1 | – | Sell |
-10,000
| Closed | -$8.78M | – | 564 |
|
|
2023
Q4 | $8.78M | Buy |
+10,000
| New | +$8.78M | 0.45% | 54 |
|
|
2020
Q4 | – | Sell |
-897
| Closed | -$502K | – | 272 |
|
|
2020
Q3 | $502K | Buy |
897
+397
| +79% | +$222K | 0.05% | 104 |
|
|
2020
Q2 | $312K | Sell |
500
-1,476
| -75% | -$921K | 0.03% | 231 |
|
|
2020
Q1 | $965K | Buy |
+1,976
| New | +$965K | 0.18% | 62 |
|
|
2019
Q2 | – | Sell |
-567
| Closed | -$233K | – | 492 |
|
|
2019
Q1 | $233K | Buy |
+567
| New | +$233K | 0.03% | 300 |
|
|
2018
Q2 | – | Sell |
-1,944
| Closed | -$669K | – | 421 |
|
|
2018
Q1 | $669K | Buy |
+1,944
| New | +$669K | 0.03% | 194 |
|
|
2017
Q4 | – | Sell |
-600
| Closed | -$268K | – | 443 |
|
|
2017
Q3 | $268K | Buy |
+600
| New | +$268K | 0.01% | 401 |
|